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Abstract
Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve
an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO).
Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT
supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT
supplementation in patients requiring veno-venous ECMO for respiratory failure.
Methods: Grifols Antithrombin Research Awards (GATRA) is a prospective, randomized, single blinded, multicenter,
controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT
supplementation to maintain a functional AT level between 80 and 120% (AT supplementation group) or not
(control group) for the entire ECMO course. In both study groups, anticoagulation will be provided with
unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin
required to maintain the ratio of activated partial thromboplastin time between 1.5 and 2. Secondary endpoints will
be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications.
Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the
heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a
future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint
including hemorrhagic events, transfusion requirements, and mortality.
Trial registration: ClinicalTrials.gov, NCT03208270. Registered on 5 July 2017.
Background
Extracorporeal membrane oxygenation (ECMO) is a
temporary life support method for patients with severe
acute respiratory failure refractory to conventional treat-
ment, and its use is continuously increasing worldwide
[1]. Since exposure of blood to the non-biologic surface
of the extracorporeal circuit induces a pro-thrombotic
state and an inflammatory response, the use of ECMO
necessitates the maintenance of hemostatic balance to
minimize the risk of both hemorrhagic and thrombotic
complications [2]. Consequently, to avoid clotting in the
extracorporeal circuit and in the patient, anticoagulation
is necessary, but it increases the risk of bleeding [3]. A
recent retrospective analysis on more than 2000 patients
reported bleeding and thrombotic complications with a
frequency of up to 45% and 60%, respectively, with
major impact on outcome [4].
Anticoagulation management during ECMO is usually
based on continuous infusion of unfractionated heparin
[5, 6]. The heparin effect is strictly dependent on
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antithrombin (AT) activity in plasma [7, 8]. Acquired AT
deficiency during ECMO is common and multifactorial
[9]: possible mechanisms include consumption due to
activated coagulation and long-term anticoagulation, but
also impaired synthesis, degradation by elastase from
activated neutrophils, and disseminated intravascular co-
agulation. AT deficiency contributes to heparin resist-
ance, with resulting difficulty in achieving therapeutic
anticoagulation and increased heparin dose [7]. Theoret-
ically, normalization of AT levels should decrease hep-
arin requirements to achieve a proper anticoagulation
target [9]. This may have a relevant clinical impact
because risk of bleeding during ECMO is reasonably
associated with higher heparin dosage, and a better
control of anticoagulation may improve patients’ out-
come [10]. However, formal recommendations on tar-
get, timing, and rate of AT supplementation during
ECMO are lacking.
Given this lack of current knowledge, we designed a
prospective randomized controlled clinical trial to evalu-
ate the effects of a protocol of AT supplementation to
achieve and maintain a normal AT activity on heparin
dose, level of anticoagulation, bleeding, and thrombotic
complications in adult patients undergoing ECMO for
respiratory failure.
The results of this study will clarify some of the un-
answered issues on AT supplementation during ECMO
and will eventually provide the basis for a subsequent
larger study on outcome.
Methods
Study design
The Grifols Antithrombin Research Awards (GATRA)
study is a pilot, prospective, randomized, single blinded,
multicenter, controlled two-arm trial that will be per-
formed on adult patients undergoing veno-venous ECMO
for severe respiratory failure. The study will be conducted
in adherence to the principles of the World Medical
Association’s Declaration of Helsinki and in accordance
with the Medical Research Involving Human Subjects Act
(WMO). The Ethics Committee of the coordinating center
(Comitato Etico Milano Area B) approved the proto-
col on April 18, 2017 (Version 1.6.7 - April 4, 2017),
and approval of the local Ethics Committees will be
required before starting the trial in the participating
centers. The study was authorized by AIFA (Agenzia
Italiana del Farmaco) on April 11, 2017 (EudraCT number
2016-004534-23) and registered at www.ClinicalTrials.gov
with code NCT03208270. Informed consent to participate
in the clinical trial will be obtained, and information on
the clinical trial will be given to each patient. If the patient
is not capable of giving informed consent at the time of
enrollment, a deferred consent will be given. The in-
formed consent will be sought by the investigator from
the patient, and the information about the study will be
given to the patient or his/her legally designated represen-
tative as soon as possible. If the patient does not consent
to the study, he/she will be informed of the right to object
to the use of data obtained from the clinical trial. The
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) checklist is provided in Additional
file 1, and the SPIRIT figure is included in the main body
of the manuscript (Fig. 1).
Setting
The GATRA trial will be performed in the intensive care
units (ICUs) of Italian ECMO referral centers. The co-
ordinating center will be Fondazione IRCCS Ca′ Granda
OspedaleMaggiore Policlinico in Milan, Italy.
Study population
Consecutive adult patients admitted to the participat-
ing centers requiring veno-venous ECMO as a sup-
port for respiratory failure will be enrolled in the study.
Exclusion criteria will be pre-existing heparin-induced
thrombocytopenia or other contraindications to heparin
use (namely high risk of bleeding after major surgery
prompting the decision to start ECMO without systemic
anticoagulation). The Consolidated Standards of Report-
ing Trials (CONSORT) diagram of the GATRA trial is
presented in Fig. 2.
Randomization
As soon as the clinical decision to initiate ECMO is
made, the patient will be enrolled in the study. Patients
will be block randomized per center through an online
automatic centralized and computerized system to one
of the two groups (1:1 ratio): AT supplementation group
or control group.
Interventions
Antithrombin supplementation group
Patients randomized to the AT supplementation group
will receive supplementation of AT concentrate to main-
tain a functional AT level between 80 and 120%. The AT
level will be measured prior to ECMO start and then
once daily and supplementation adjusted accordingly. In
the study group, AT concentrate supplementation will be
interrupted when AT levels exceeds 120% and resumed
as soon as the levels drop below 80%. The protocol for
AT supplementation is illustrated in Fig. 3.
Control group
Patients randomized to the control group will not re-
ceive supplementation of AT unless heparin resistance
occurs. The following safety criteria will be applied to
define “heparin resistance”: when a patient in the control
group requires more than 35 IU/kg/h of heparin and
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his/her AT plasma level is equal to or lower than 50%.
Dosage regimen for AT supplementation in the control
group will follow the same supplementation algorithm
as in the treatment group. AT will be supplemented to
achieve an AT plasma level higher than 50%. The AT
level will be measured prior to ECMO start and then
once daily.
Anticoagulation protocol for both groups
In both study groups, anticoagulation during ECMO will
be provided with unfractionated heparin following the
institutional protocol of the coordinating center, as pre-
viously published [10] (Fig. 4). Briefly, a heparin bolus of
50–70 IU/kg, depending on baseline activated partial
thromboplastin time (aPTT) value, will be administered
at ECMO start, followed by 18 IU/kg/h continuous infu-
sion. For the first 12 h after ECMO start, anticoagulation
will be monitored with activated clotting time (ACT)
(therapeutic range 180–210 s, performed every 1 or 2 h
according to the standardized protocol). From the 13th
hour on, anticoagulation will be guided by aPTT, with a
target aPTT ratio (patient-to-normal) range of 1.5–2.0.
The frequency of aPTT measurements may vary from a
minimum of three times per day to a maximum of six
depending on the standardized protocol. When the
aPTT value falls well below the desired range, a bolus of
heparin will be administered. When the value is too
high, infusion will be stopped for either 30 or 60 min.
In both groups the following safety criteria will be
used: in case of major surgery, during the first 24 h
after operation, minimal levels of anticoagulation will
be allowed to minimize the risk of bleeding. In case
of minor bleeding (i.e., dripping from the site of the
vascular catheter’s cannulation), physicians shall main-
tain anticoagulation targeted to the lower level (i.e.,
aPTT ratio 1.5). In case of clinically significant bleed-
ing, heparin infusion may be interrupted until bleed-
ing ceases; infusion will be restored starting at 50–
70% of the pre-existing dose. No changes will be
made to the AT dosage regimen.
Criteria for transfusions of blood products and replacement
of the ECMO circuit
For the entire duration of the study, hemoglobin will be
maintained at > 10 g/dL, platelet count > 50,000/mm3,
and fibrinogen > 150 mg/dL, through packed red blood
cells, platelets, and fresh frozen plasma and/or fibrino-
gen concentrate transfusions, respectively.
To standardize the clinical decision to replace the
ECMO circuit with a new one, an ad hoc “circuit
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT** Before ECMO start
ECMO 
start
Daily for the 
entire ECMO 
duration
ICU 
discharge/death
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Antithrombin 
supplementation group X
Control group
ASSESSMENTS:
Screening test for 
thrombofilia
X X
Coagulation and ECMO
parameters
X
Heparin dose, transfusions, 
bleeding and thrombotic 
events
X
ECMO duration, ICU LOS 
and 28-day survival
X
Fig. 1 Intervention and assessment schedule
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change-out score” was developed that considers the per-
formance of the oxygenator, signs of coagulation activa-
tion by the extracorporeal circuit (e.g., drop in platelet
count, increase in D-dimer level, and decrease in fibrino-
gen level), and the presence of hemolysis. The “circuit
change-out score” includes two different conditions (A
and B) defined by different sets of criteria. Condition A
requires all the following three criteria to be satisfied:
decrease in platelet count greater than 50% in 48 h; de-
crease in fibrinogen level greater than 33% in 48 h; in-
crease in D-dimer level greater than 100% with D-dimer
level higher than 30,000 ng/mL. Condition B requires
two of the following three criteria to be satisfied: platelet
count lower than 50,000/mL; fibrinogen lower than 150
mg/dL; D-dimer higher than 50,000 ng/mL, provided
that D-dimer elevation is one of the two “B” conditions.
Stopping rules
Patients will be supplemented with AT during ECMO
according to the assigned group and followed up for the
entire duration of ECMO. AT supplementation will be
stopped at ECMO discontinuation.
Premature discontinuation of the study will be allowed
when one of the following conditions occurs: (1) death;
(2) onset of heparin-induced thrombocytopenia requir-
ing shift to an alternative anticoagulant drug to heparin;
(3) unexpected circumstances that prevent proper hep-
arin or AT supplementation.
End of follow-up
Enrolled patients will be observed until ICU discharge
or death, whichever comes first.
Study endpoints
Primary endpoint
The primary endpoint will be the amount of heparin in-
fused to each patient, calculated as the total adminis-
tered heparin per kilogram of body weight (including
boluses) divided by the total duration of heparin infusion
in hours (IU/kg/h).
Secondary endpoints
Adequacy of anticoagulation will be assessed through
anti-factor Xa levels.
Fig. 2 CONSORT flow diagram
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Fig. 3 Protocol for anthithrombin supplementation
Fig. 4 Anticoagulation protocol
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The study will also provide a preliminary evaluation of
the safety of AT supplementation by comparing the inci-
dence of the following adverse events in the two study
groups: bleeding complications, classified according to a
modified version of the Bleeding Academic Research
Consortium score to our clinical settings [11, 12]; blood
products transfusion requirements; patient’s or circuit
thrombosis.
Data collection
At enrollment, we will anonymously collect patients’
demographic information (e.g., age, sex, height, weight),
past (e.g., chronic medications including anticoagulant
and antiplatelet drugs) and recent (e.g., etiology of the
acute respiratory failure) medical history, and ECMO
configuration with cannulation sites. A blood sample will
be drawn from patients to test inherited or acquired
thrombophilia (proteins C and S, Factor (F) V G1691A
and FII G20210A, lupus anticoagulant, anti-cardiolipin,
and anti-β2-glycoprotein 1 antibodies).
The following data will be recorded every day for the
whole study duration: daily heparin dosage; coagulation
parameters (including D-dimer, fibrinogen, aPTT ratio,
prothrombin time (PT) ratio, anti-factor Xa, antithrom-
bin activity, ACT); complete blood count; indexes of
hemolysis (hemoglobin, free hemoglobin, and haptoglo-
bin levels); transfusion of blood products.
Bleeding and thrombotic events will also be recorded.
Within 24 h after ECMO removal, a Doppler ultrasonog-
raphy of the cannulated vessels and of the vena cava will
be performed to exclude thrombosis due to vascular
cannulation. Functional ECMO parameters will be eval-
uated once per day (membrane oxygenator shunt, blood
flow resistance, oxygenation performance) and recorded.
Evaluation of clinical outcome will include duration of
ECMO, ICU length of stay, and survival at 28 days.
Collected data will be entered in an electronic case
report form (eCRF) available online at a dedicated web-
site (https://ecmostudy.fbk.eu), with protected individual
access for each participating center. Patient data will be
anonymous and coded according to a number. The
eCRF includes tools to promote data quality, such as
range checks for data values. Data monitoring will be
performed by means of queries on the database done by
statisticians and analyzed to identify abnormalities and
inconsistencies.
Statistical considerations
All statistical analyses will be done with Stata version
14.1 (StataCorp, College Station, TX, USA) in the coord-
inating centers at the Epidemiology Unit of Fondazione
IRCCS Ca′ Granda Ospedale Maggiore Policlinico in
Milan, Italy.
Sample size
Sample size is calculated using the confidence interval
approach upon the primary outcome measure of reduc-
tion of heparin dose in the study group treated with AT
to maintain a normal AT plasma level (considered to be
a level higher than 80%) compared to the control group.
Preliminary data from patients in ECMO, cared for with
the same heparin titration protocol of this study, showed
that the mean heparin dosage was 18 IU/kg/h and 13 IU/
kg/h in patients with AT activity lower and higher than
the median (73.5%), respectively. Assuming an estimated
difference of 5 IU/kg/h of heparin between the two
groups, a sample size of 40 patients (20 in each treat-
ment group) would yield a 95% confidence interval of
average heparin reduction from 1 to 9 IU/kg/h).
Proposal for analysis
Baseline variables will be compared between each ran-
domized arm to assess the randomization performance
and baseline balance between arms. We will not per-
form statistical testing for baseline comparison between
arms, because any differences in baseline characteristics
are consequences of chance due to randomization. All
analyses will be conducted in accordance with the
intention-to-treat principle and in accordance with the
CONSORT statement.
For the primary and secondary outcomes, continuous
variables will be reported as means ± standard deviations
or medians and 25–75% interquartile ranges. Categorical
variables will be reported as absolute and relative fre-
quencies. Differences between groups will be tested
using Mann-Whitney and chi-square or Fisher’s exact
tests, as appropriate. Estimates of the effects and their
confidence intervals will also be reported. In case of evi-
dent imbalances for key baseline variables between
treated patients and controls, we will perform statistical
adjustment using regression models.
For repeated outcomes within subject, the association
between AT dosage, heparin dosage, bleeding, and moni-
toring methods will be evaluated using random-effect
models.
Study organization
This is an investigator-initiated trial. Two principal inves-
tigators (MP and GG) designed the study protocol. Each
participating center will indicate a local investigator in
charge of the study. The principal investigators are re-
sponsible for administrative management and communi-
cation with the local investigators and for helping the
participating clinical sites in trial management, record
keeping, and data management. The study will be
conducted with the financial support of Grifols
(GATRA – Antithrombin Research Awards 2016).
Funders will not have any role in the analysis and
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interpretation of the study results or in the decision to sub-
mit the report for publication. The local investigators guar-
antee the integrity of data collection. All adverse events will
be monitored by the coordinating center and reported to
AIFA according to the national legislation. Specific patient
insurance will be granted to cover all unexpected adverse
events caused by the study interventions.
Ancillary study
The rationale for AT supplementation during ECMO is also
based on its coagulation-independent anti-inflammatory
effects. Some of these mechanisms include endothelial
release of prostacyclin that inhibits aggregation and
activation of platelets [13, 14] and the reduction of
various cytokines and chemokines from the endothe-
lial cells [15, 16].
To evaluate markers of inflammation and epithelial
and endothelial damage, 4 aliquots of plasma, 0.5 mL
each, will be obtained from each patient in the GATRA
study, by centrifugation of ethylenediaminetetraacetic
acid (EDTA) blood at 3000 revolutions per minute
(RPM) for 15 min at 4 °C, prior to ECMO start, 24 h
after ECMO start, 72 h after ECMO start, before ECMO
removal, and 7 days after ECMO removal (or before dis-
charge from the ICU if this happens first). Then the ali-
quots will be stored, shortly after collection, at − 80 °C
until levels of tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, IL-6, IL-8, IL-10, endocan, and syndecan are
measured. At the same time points we will also collect
blood to evaluate the transcriptional profile of circulat-
ing cells in whole blood. To identify changes in the tran-
scriptional activation of genes involved in inflammation,
epithelial, and endothelial damage, 2.5 mL of whole
blood will be collected in RNA PAXgene tubes prior
to ECMO start and 24 and 72 h after ECMO start.
Specimens will be stored at − 20 °C until transcrip-
tome profiling is performed [17].
Discussion
GATRA is a pilot randomized controlled trial aimed at
testing a protocol of AT supplementation in patients on
ECMO for severe respiratory failure. It will assess the
feasibility and the safety of prolonged AT supplementa-
tion to target normal AT levels and its efficacy in de-
creasing the heparin dose and improving anticoagulation
adequacy. If positive, it might provide the basis for a
future larger trial aimed at verifying the impact of AT
supplementation on a composite outcome endpoint in-
cluding hemorrhagic events, transfusion requirements,
and mortality.
Antithrombin supplementation during ECMO
Heparin mainly exerts its anticoagulant effect by binding
AT and facilitating the inhibition of thrombin by AT.
When heparin binds to AT, it converts AT from a slow
to a rapid thrombin inhibitor. Therefore, the therapeutic
activity of heparin depends on the availability of circu-
lating AT. The heparin/AT also inhibits factor Xa and to
a lesser extent other activated coagulation factors (Xa,
IXa, XIa, and XIIa) [18]. Another possible anticoagulant
mechanism of heparin includes the release of tissue fac-
tor pathway inhibitor from endothelial cells [19]. Al-
though AT is needed by heparin to properly exploit its
anticoagulant activity, there is no consensus on AT sup-
plementation during ECMO. Guidelines suggest supple-
menting AT in ECMO only when its deficiency coexists
with heparin resistance [6]. Few studies evaluated the ef-
fect of AT supplementation during ECMO without a
consensus on the target level to be maintained. Small
and retrospective studies in the pediatric population ex-
amined the administration of AT during ECMO but
yielded inconclusive results, with some reporting no ef-
fects on heparin dose and bleeding [20–22] and others ob-
serving decreased heparin requirements [23–25] and
fewer transfusions [25]. These contrasting results might
be explained by the high variability in dosing schemes, tar-
get levels, timing, and duration of AT supplementation.
Development of the protocol for AT supplementation:
practical and operational issues
Since dosing recommendations are not provided for
acquired AT deficiency, the protocol for AT supplemen-
tation was developed following manufacturer recom-
mendations for hereditary deficiency. Supplementation
dosing is based on patient body weight and the differ-
ence between the actual and the desired AT activity. A
level of AT activity corresponding to the normal range
(80–120%) was chosen as the target for supplementa-
tion. The calculated dose was rounded up to the nearest
vial size, and dose tiers were created using ranges of AT
activity to minimize bedside calculations. The protocol
mandates, for patients in the AT supplementation group,
the administration of a loading dose of AT upon ECMO
cannulation. As the level of AT activity before ECMO
start was expected not to be available for most patients,
the loading dose is based solely on the patient body
weight. Subsequent dose adjustments are based on the
patient body weight and the plasma AT activity, which
must be measured daily. Patients with a plasma AT ac-
tivity between 80 and 120% will receive a maintenance
dose, which will be increased by 1000 IU if the plasma
AT activity is lower than 80%. Observational studies sug-
gest that intermittent administration of AT is less effective
than continuous infusion in correcting AT deficiency;
moreover, rapid AT binding to heparin complexes after
bolus administration could theoretically increase the risk
for bleeding. Based on the clinical experience of our and
other ECMO centers [26, 27], administration of AT via an
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extended infusion decreases heparin rate modifications
and avoids AT levels fluctuations, without increasing the
risk of major bleeding. Therefore, the protocol prescribes
AT administration by extended infusion both for loading
and maintenance doses.
Study endpoints
Hemorrhagic complications remain a major cause of
morbidity and mortality in ECMO patients [4]. Hence,
protocols to guide anticoagulation management are key
in the management of these patients. Physiological con-
siderations suggest that normalization of AT levels
might improve adequacy of heparin anticoagulation and
possibly decrease the risk of bleeding. Indeed, in adult
patients undergoing ECMO for respiratory failure, lower
AT levels were associated with increased need for
transfusion [26], and AT supplementation facilitated
achievement of target anticoagulation without increas-
ing heparin dosage [27]. A higher degree of anticoa-
gulation [28] is associated with hemorrhagic events
during ECMO, but risk of bleeding is multifactorial
and does not depend solely on anticoagulation. We
chose the reduction of heparin dose as the primary
endpoint for this pilot trial; however, it is conceivable
that larger studies will be needed to detect the hy-
pothesized effect on clinical outcome.
Study strengths and limitations
One of the strengths of the study is that the protocol
contains a well-defined heparin anticoagulation protocol,
which has already been adopted in a previous multicen-
ter trial [29]. This should facilitate its application and
minimize deviations in anticoagulation management
which could jeopardize the effect of AT supplementation
on study endpoints. Although the decision to transfuse
blood products is clinical, the protocol recommends
well-defined targets for hemoglobin, platelet count, and
fibrinogen. Similarly, criteria for considering replace-
ment of the ECMO circuit are provided.
One limitation of the GATRA trial is that blinding is
not possible due to the nature of the intervention. How-
ever, the factors that can potentially affect the primary
outcome (in particular, heparin dose adjustments and
transfusion of blood products) are regulated by the
protocol.
Trial status
The GATRA trial is currently recruiting patients. The
protocol was approved by the Ethics Committee of the
coordinating center on April 18, 2017. The first patient
was enrolled on August 8, 2017. As of September 9
2018, 36 patients have been screened and 23 patients
have been randomized (11 interventional group, 12
control group) in the coordinating center. Recruitment
is expected to be completed in May 2019.
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